Currently, only a few early-phase clinical studies (phases 1 and 2) have investigated anti-LAG-3 monoclonal antibodies (mAbs) as monotherapy or in combination with other ICIs such as anti-PD-1 and anti-CTLA-4 in advanced solid tumors, including ovarian cancer. This evidence concerns the gene PDCD1 and ovarian carcinoma.